News · 26 weeks15-100%
2025-12-142026-06-07
Mix590d
- Other2(40%)
- SEC Filings2(40%)
- Insider1(20%)
Latest news
25 items- INSIDERLarge owner Strome Mark E bought $200,000 worth of shares (100,000 units at $2.00) (SEC Form 4)4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- PRZIVO Bioscience Secures Commercial-Scale Manufacturing Agreement with Cyanotech Corporation for Zivolife™ Algal BiomassPartnership with 40-Year Industry Leader Positions ZIVO to Meet Anticipated Global Commercial Demand Zivo Bioscience, Inc. (OTCQB:ZIVO) ("ZIVO" or the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced the signing of a manufacturing agreement with Cyanotech Corporation to grow, cultivate and process ZIVO's proprietary algal biomass for its Zivolife™ product line. ZIVO is advancing Zivolife™ toward commercial applications across animal health, human nutrition and functional ingredients markets. This agreement with Cyanotech, one of the world's most establ
- SECSEC Form EFFECT filed by Zivo Bioscience Inc.EFFECT - Zivo Bioscience, Inc. (0001101026) (Filer)
- SECZivo Bioscience Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
- PRZIVO Bioscience Provides Special Letter to ShareholdersZIVO Bioscience, Inc. (OTCQB:ZIVO), today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne. Dear Fellow Shareholders, I am writing to inform you of a significant and carefully considered decision by the Board of Directors of ZIVO Bioscience, Inc. ("ZIVO" or the "Company"): we intend to deregister the Company's securities with the Securities and Exchange Commission and cease public reporting. This letter explains the reasoning behind this decision, what it means for shareholders, and how it positions ZIVO for its next phase of growth. A Decision Made in the Best Interests of Shareholders After careful deliberation, we have
- INSIDERDirector Yaldoo Laith L bought $14,998 worth of shares (1,543 units at $9.72) (SEC Form 4)4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Zivo Bioscience Inc.SCHEDULE 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)
- INSIDERLarge owner Strome Mark E bought $195,400 worth of shares (20,000 units at $9.77) (SEC Form 4)4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- INSIDERDirector Yaldoo Laith L bought $24,997 worth of shares (2,434 units at $10.27) (SEC Form 4)4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- INSIDERDirector Cornell Alison A bought $99,995 worth of shares (11,709 units at $8.54), increasing direct ownership by 4% to 279,481 units (SEC Form 4)4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- INSIDERPresident and CEO Payne John Bernard bought $99,995 worth of shares (11,709 units at $8.54), increasing direct ownership by 148% to 19,618 units (SEC Form 4)4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- INSIDERDirector Maggiore Christopher D. bought $14,993 worth of shares (1,766 units at $8.49), increasing direct ownership by 0.34% to 519,292 units (SEC Form 4)4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- INSIDERDirector Yaldoo Laith L bought $14,993 worth of shares (1,766 units at $8.49) (SEC Form 4)4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- INSIDERNew insider Sullivan William A. claimed no ownership of stock in the company (SEC Form 3)3 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- SECZivo Bioscience Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
- INSIDERDirector Yaldoo Laith L bought $24,993 worth of shares (2,777 units at $9.00) (SEC Form 4)4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- SECSEC Form 10-Q filed by Zivo Bioscience Inc.10-Q - Zivo Bioscience, Inc. (0001101026) (Filer)
- INSIDERLarge owner Strome Mark E bought $249,996 worth of shares (20,259 units at $12.34) (SEC Form 4)4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- INSIDERDirector Yaldoo Laith L bought $19,991 worth of shares (1,659 units at $12.05) (SEC Form 4)4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- INSIDERDirector Maggiore Christopher D. bought $284,421 worth of shares (23,682 units at $12.01), increasing direct ownership by 5% to 517,526 units (SEC Form 4)4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- INSIDERSEC Form 4 filed by Director Yaldoo Laith L4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- INSIDERSEC Form 4 filed by Director Maggiore Christopher D.4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- INSIDERSEC Form 4 filed by Director Cornell Alison A4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- INSIDERDirector Yaldoo Laith L bought $244,999 worth of shares (15,322 units at $15.99) (SEC Form 4)4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
- SECZivo Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
ZIVO FAQ
6 questionsWhat does Zivo Bioscience Inc. do?
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company was formerly known as Health...Where does ZIVO stock trade?
Zivo Bioscience Inc. (ZIVO) is listed on NASDAQ.What sector and industry is ZIVO in?
Zivo Bioscience Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ZIVO?
Zivo Bioscience Inc. has had 1 recent analyst action on file. The most recent action was from Maxim Group: Buy with a $900.00 price target on 2021-12-15. Recent price targets cluster around $900.00.What companies are similar to ZIVO?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ZIVO side-by-side with any of them on Quantisnow.How can I track ZIVO on Quantisnow?
Quantisnow aggregates Zivo Bioscience Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZIVO to receive live email and push alerts on every new disclosure.